Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.
Integrated Regional Information Networks - April 4, 2000
"This offer is an over time donation in that it does have a time limit on it," Nyide told IRIN. She added that the details of Pfizer's offer still had to be discussed with the department of health. "We have sent a letter through to the department outlining our proposal and we now are waiting for their response."
Cryptococcal meningitis is an infection of the brain and affects between eight and ten percent of AIDS patients in South Africa annually. If taken in time, Diflucan can help to contain the disease and relieve pain and turn a normally terminal disease into a chronic but treatable illness. Initially in the first two weeks of treatment patients are required to take two tablets a day followed by one tablet daily for the rest of their lives. It is not yet clear if the South African government will accept Pfizer's offer. The government has recently, amid controversy questioned the safety of AIDS treatment drugs. The ministry of health told IRIN that it had received Pfizer's letter and was studying the offer.
AIDS activists in South Africa are divided on the proposal. The Treatment Action Campaign said that it welcomed the decision and have called on other major pharmaceutical companies to emulate Pfizer's example. "In particular, we call on Glaxo Wellcome to follow Pfizer's lead and make AZT available for reducing the risk of mother-to-child transmission."
However some AIDS campaigners have expressed concerns about details of the proposal. "It's all very well to say here is a donation, but what happens to patients when that donation runs out. You can't start this kind of treatment and then suddenly stop. A more long term solution has to be found. One option would be to introduce a system of pay as you earn or introduce generics into the country," an AIDS activist told IRIN.
In its response Medecins Sans Frontieres (MSF) said in a statement on Tuesday that it welcomed the announcement but cautioned that a "donation was not a long term solution". "We're delighted that at least one step has been made toward providing treatments for AIDS patients - but is it a sustainable option?" MSF said. Last year Pfizer's profits from the sale of Diflucan was an estimated US $1 billion. A single dose costs between US $10 and US $14.
000404
IR000403
Copyright © 2000 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .